PMID- 29029471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 39
DP  - 2017 Sep 12
TI  - Protective effect of resveratrol against light-induced retinal degeneration in 
      aged SAMP8 mice.
PG  - 65778-65788
LID - 10.18632/oncotarget.19473 [doi]
AB  - PURPOSE: The purpose of this study was to determine the protective effects of 
      Resveratrol (RESV) on acute bright light-induced retinal degeneration in aged 
      senescence accelerated mouse strain. METHODS: Ten three-month-old male SAMP8 mice 
      (prone to aging) were randomly assigned to two experimental dietary groups: one 
      untreated group and one RESV treatment group (n=20 eyes for each group). After 30 
      days of treatment, mice were exposed to intense bright light. Ten male SAMR1 mice 
      (resistant to aging) served as control (n=20 eyes). The protective effects of 
      RESV administration on light-induced retinal degeneration in SAMP8 strain as well 
      as the effect of bright light damage in the retinas of SAMP8 mice were analyzed 
      by electroretinography (ERG), retinal histology, mRNA, protein and lipid profile. 
      RESULTS: 68%-85% of a-wave amplitude and 72%-92% of b-wave amplitude were 
      persevered by RESV in SAMP8 mice that were exposed to light damage. Also, RESV 
      preserved their photoreceptor nuclei. mRNA expression of neuroprotective factors 
      leukemia inhibitory factor (LIF), brain derived neurotrophic factor (BDNF), 
      oncostatin M (OSM), cardiotrophin 1(CT-1) and cardiotrophin-like cytokine (CLC) 
      were up-regulated 28, 8, 7, 5 and 9-fold in SAMP8 mice after RESV treatment. In 
      addition, RESV could suppress the NF-kappaB pathway by down-regulating the expression 
      of pIkappaB. Light damage led to increase of saturated FA, monoenoic FA, n6 PUFA and 
      n6/n3 ratio and decrease of Docosahexaenoic acid (DHA). There was no significant 
      difference on DHA and the ratio of n6/n3-FA between the untreated and RESV 
      treated SAMP8 mice. CONCLUSIONS: Collectively, our study provides evidence that 
      RESV prevents light-induced retinal damage associated with aging.
FAU - Liu, Zhirong
AU  - Liu Z
AD  - Department of Ophthalmology, Hospital of University of Electronic Science and 
      Technology of China and Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
FAU - Wu, Zhengzheng
AU  - Wu Z
AD  - Department of Ophthalmology, Hospital of University of Electronic Science and 
      Technology of China and Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
FAU - Li, Jie
AU  - Li J
AD  - Department of Ophthalmology, Hospital of University of Electronic Science and 
      Technology of China and Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
FAU - Marmalidou, Anna
AU  - Marmalidou A
AD  - Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard 
      Medical School, Boston, MA 02114, USA.
FAU - Zhang, Ruifan
AU  - Zhang R
AD  - Department of Ophthalmology, Hospital of University of Electronic Science and 
      Technology of China and Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
FAU - Yu, Man
AU  - Yu M
AD  - Department of Ophthalmology, Hospital of University of Electronic Science and 
      Technology of China and Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
LA  - eng
PT  - Journal Article
DEP - 20170722
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5630371
OTO - NOTNLM
OT  - SAMP8 mice
OT  - aging
OT  - light damage
OT  - resveratrol
OT  - retinal degeneration
COIS- CONFLICTS OF INTEREST The study is not industry sponsored. The authors have no 
      disclosures with regard to this report. There are no conflicts of interest.
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:01
PMCR- 2017/09/12
CRDT- 2017/10/15 06:00
PHST- 2017/03/13 00:00 [received]
PHST- 2017/06/24 00:00 [accepted]
PHST- 2017/10/15 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:01 [medline]
PHST- 2017/09/12 00:00 [pmc-release]
AID - 19473 [pii]
AID - 10.18632/oncotarget.19473 [doi]
PST - epublish
SO  - Oncotarget. 2017 Jul 22;8(39):65778-65788. doi: 10.18632/oncotarget.19473. 
      eCollection 2017 Sep 12.